Cargando…

A Possible Advantage of Glucagon-Like Peptide 1 Receptor Agonist in Kidney Transplant Recipients With Type 2 Diabetes

Diabetic kidney disease (DKD), a devastating complication of diabetes, is one of the leading causes of end stage kidney disease (ESKD). Kidney transplantation provides superior outcomes for ESKD patients with type 2 diabetes, giving opportunities to be free from dialysis, but needs lifetime immunosu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sato, Tetsuhiko, Ohara, Emi, Ozone, Chikafumi, Okazaki, Mikako, Fuse, Sachiho, Sasaki, Rie, Azuma, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Diabetes Mellitus and Glucose Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090345/ http://dx.doi.org/10.1210/jendso/bvab048.826

Ejemplares similares

Anaphylactic Reaction to Dulaglutide: A Glucagon Like Peptide- 1 Receptor Agonist
por: Quadri, Hamza, et al.
Publicado: (2021)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

SUN-164 Use of Metformin, Premixed Insulin, and Glucagon-Like Peptide-1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes Mellitus
por: Fazeli, Sasan, et al.
Publicado: (2019)

Scientific and Regulatory Considerations for the Approval of the First Generic Glucagon
por: Pang, Eric, et al.
Publicado: (2021)

SUN-165 The Largest Single-Center Experience of GLP-1 Receptor Agonists as a Safe and Effective Agent for the Management of Diabetes in Solid Organ Transplant (SOT) Recipients
por: Singh, Priyamvada, et al.
Publicado: (2019)

MON-LB032 Real World Evidence Data on the Role of Sodium/Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonist in Chronic Kidney Disease Stage 3 Patients beyond Glycemic Control, at Glycemia Clinic- Kuwait
por: Shaghouli, Amna, et al.
Publicado: (2019)

OR22-3 Closed-Loop Glucagon Pump: A Novel and Effective Strategy for Post-Bariatric Hypoglycemia
por: Mulla, Christopher, et al.
Publicado: (2019)

OR28-5 Bile Acid Sequestration Accelerates Glucagon Receptor-Mediated Body Weight Loss in Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2019)

MON-LB115 Ready-To-Use Glucagon for the Prevention of Exercise-Induced Hypoglycemia in a Clinical Research Setting
por: Aronson, Ronnie, et al.
Publicado: (2020)

SAT-655 Bile Acid Sequestration Synergistically Accelerates Glucagon Receptor-Stimulated Body Weight Loss in Diet-Induced Obese Mice
por: Kim, Teayoun, et al.
Publicado: (2020)

OR26-07 Mild Physiologic Hyperglycemia Does Not Affect Glucose Mediated but Impairs Insulin-Mediated Suppression of Plasma Glucagon in Healthy Normal Glucose Tolerant Subjects
por: Tripathy, Devjit, et al.
Publicado: (2020)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

MON-LB110 A Phase 2 Evaluation of a Ready-To-Use Liquid Stable Continuous Subcutaneous Glucagon Infusion for the Treatment of Hypoglycemia Associated Autonomic Failure
por: Pettus, Jeremy H, et al.
Publicado: (2020)

Prospective Longitudinal Study Evaluating Comprehensive Metabolic and Life Style Characteristics of Pancreas Transplantation Recipients
por: Kaur, Ravinder Jeet, et al.
Publicado: (2021)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis
por: Piccoli, Giovana Fagundes, et al.
Publicado: (2021)

MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)
por: Broome, David Tyler, et al.
Publicado: (2020)

SAT085 Oral Glucagon-like Peptide-1 Receptor Agonist As Adjuvant Treatment In HNF1A-MODY
por: Tyler Broome, David
Publicado: (2023)

SAT-169 Selective Nonpeptide Somatostatin Subtype 5 (sst5) Agonists Suppress Glucose- and Sulfonylurea-Induced Insulin Secretion in Rats
por: Sturchler, Emmanuel, et al.
Publicado: (2019)

ODP083 Burosumab Treatment for Fibrous dysplasia/McCune-Albright Syndrome with Severe Spine Deformity
por: Sato, Tetsuhiko, et al.
Publicado: (2022)

Selective Somatostatin 5 (SST5) and Somatostatin 2 (SST2) Nonpeptide Agonists Potently Suppress Glucose- and Tolbutamide-Stimulated Dynamic Insulin Secretion From Isolated Human Islets
por: Rico, Elizabeth, et al.
Publicado: (2021)

THU275 Tacrolimus Levels And Kidney Function In Kidney Transplanted (KT) Patients With Diabetes On Glucagon Like-1 Receptor Agonists (GLP1-RA)
por: Campana, Mario S, et al.
Publicado: (2023)

Efficient Restoration of Beta Cell Dedifferentiation by Calorie Restriction With High Fat/Low Carbohydrate Diet in Obese Diabetes Model and the Possible Role of GLP-1
por: Ishida, Emi, et al.
Publicado: (2021)

Analysis of Novel Histone Methylase MLL Function for Glucose Metabolism in Mouse Pancreas
por: Yoshino, Satoshi, et al.
Publicado: (2021)

Tgm2-p62-p53 Complex May Function as an Autophagic Regulator Through Fyn and Involve in Diabetic Kidney Disease
por: Uehara, Ryota, et al.
Publicado: (2021)

SUN-LB110 The Nutrition Education Using a Health Care Application With Artificial Intelligence in Patients With Diabetes Mellitus
por: Higashitani, Takuya, et al.
Publicado: (2020)

OR24-4 Targeting Hyperglucagonemia Reverses Glucagon Resistance
por: Bernal-Mizrachi, Ernesto, et al.
Publicado: (2022)

OR34-06 Gliclazide Restores Appropriate Glucagon Suppression During OGTT In MODY3 & MODY1 Patients: Results Of The “Glucagon In MODY” Study
por: Spiliotis, Ioannis Ilias, et al.
Publicado: (2023)

THU338 Risks Of Stroke, Its Subtypes And Atrial Fibrillation Associated With Glucagon-like Peptide 1 Receptor Agonists Versus Sodium-glucose Cotransporter 2 Inhibitors: A Real-world Population-based Study In Hong Kong
por: Lui, David, et al.
Publicado: (2023)

RF04 | PSUN233 Design of an Ultra-Stable Insulin/Glucagon Fusion Protein
por: Grabowski, Rachel, et al.
Publicado: (2022)

LBODP066 A Conservative Approach To The Management Of Glucagon Receptor (GCCR) Mutation (Mahvash Syndrome)
por: Morgenthau, Ari, et al.
Publicado: (2022)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

MON-LB024 Episodic Hypoglycemia in Non-Diabetics: Differentiating Distressing from Deadly
por: Windham, Mary, et al.
Publicado: (2019)

MON-158 Association between Famine Exposure in Early Life with Insulin Resistance and β-cell Dysfunction in Adulthood
por: Wang, Yuying, et al.
Publicado: (2019)

MON-159 Increased Gluconeogenesis and Lower Glycogenolysis in Patients with Non-Selective Compared Selective Insulin Resistance
por: Sekizkardes, Hilal, et al.
Publicado: (2019)

MON-164 The Non-insulin-based METS-IR Index Combined With Liver Transaminases Improves Prediction Of Fatty Liver And Fibrosis
por: Bello-Chavolla, Omar, et al.
Publicado: (2019)

MON-162 Hepatic DNA Damage Induced by ENDS Is Associated with Decreased Levels of NAD+
por: Espinoza-Derout, Jorge, et al.
Publicado: (2019)

MON-150 Phone Call Reminders and Mobile Health Apps: Do They Help Our Diabetic Patients?
por: Lu, Kevin, et al.
Publicado: (2019)

MON-182 Adaptable Amperometric Biosensor Platforms for the Diagnosis of Endocrine Disorders
por: Labban, Najwa, et al.
Publicado: (2019)

MON-129 An Unusual LMNA Mutation Causing a Complex Phenotype: When the Genetic Diagnosis Uncovers Novel Features
por: Andrade, Natália, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7f6gialkvml3abako6vo531dgr